Re-appointment of Mr. Yogesh Agrawal as Chairman & Managing Director of the Company for the period of five (5) years with effect from 07.09.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 15.2 pts less than Nifty Microcap 250 and 15.2 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board of Genomic Valley Biotech Ltd, at its meeting on 07 August 2025, approved the re-appointment of promoter Mr. Yogesh Agrawal as Chairman & Managing Director for a 5-year term effective 07 September 2025. He has been on the board since 07.09.2015, holds 14.27 lakh equity shares, and is the husband of existing director Mrs. Parul Agrawal. The board also approved Q1 FY26 (quarter ended 30 June 2025) unaudited results, showing a profit of about Rs. 2.47 lakh versus a loss of Rs. 8.35 lakh in the preceding quarter, though sharply lower than the Rs. 12.76 lakh profit in Q1 FY25. Additionally, M/s SBR & Co. LLP was appointed as Secretarial Auditor for FY25-30, and Mr. Navjyoti Kumar Jha was appointed as Internal Auditor for FY25-26. Statutory auditors Andros & Co. issued an unmodified limited review report on the results.
Continuity at the top with the promoter-founder re-appointed for another 5 years provides leadership stability, but the shrinking year-on-year profitability and extremely low revenue base raise concerns about business scale and growth trajectory.